Status:
COMPLETED
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This expanded access study will assess the safety and efficacy of intravenous bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) in combination with fluoropyrimidine-based chemotherapy as ...
Eligibility Criteria
Inclusion
- Previously untreated metastatic colon or rectal cancer;
- Scheduled to begin fluoropyrimidine-based chemotherapy as a first line treatment.
Exclusion
- Prior chemotherapy for metastatic colon or rectal cancer;
- Planned radiotherapy for underlying disease;
- central nervous system metastases;
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before study start.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT01169558
Start Date
May 1 2006
End Date
July 1 2009
Last Update
December 8 2016
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Belo Horizonte, Brazil, 30140-083
2
Belo Horizonte, Brazil, 30150-221
3
Belo Horizonte, Brazil, 30150321
4
Brasília, Brazil, 70390-150